Nuvation Bio Profit Margin

The latest profit margin for NUVB is -88.19% as of June 2026. That compares with -1413.43% in the prior-year period — up 93.8% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside Nuvation Bio's historical trend and sector peers before judging valuation or financial health.

Over the past year, NUVB's profit margin moved from -1413.43% to -88.19% — a 93.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Nuvation Bio's valuation or profitability profile.

Against Healthcare companies, NUVB currently prints -88.19% for profit margin, while the sector average sits near 13.89%. That is roughly 734.7% below the sector mean. Large gaps often invite a closer look at Nuvation Bio's growth, margins, and balance sheet.

Profit Margin shows how effectively Nuvation Bio converts resources into returns. At -88.19%, NUVB may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -1413.43% in the prior-year period — up 93.8% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting NUVB's profit margin (-88.19%), review year-over-year change from -1413.43%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.